MarketScreener Homepage > Equities > NASDAQ OMX STOCKHOLM > Isofol Medical AB (publ) ISOFOL SE0009581051

Report

End-of-day quote NASDAQ OMX STOCKHOLM - 01/22
28.2	SEK		-2.08%

2020

ISOFOL MEDICAL : reaches 440 patients in global Phase III AGENT study

2020

DNB MARKETS - ISOFOL MEDICAL : Full steam ahead

2020

DNB MARKETS : Isofol Medical - Licensing deal for Canada

Summary

Quotes 5-day view End-of-day quote.

End-of-day quote Nasdaq Omx Stockholm

01/18/2021	01/19/2021	01/20/2021	01/21/2021	01/22/2021	Date
29.8	29.1	29.2	28.8	28.2	Last
395311	201445	297982	267661	212686	Volume
-1.97%	-2.35%	+0.34%	-1.37%	-2.08%	Change

Financials

Sales 2020	19,9 M 2,41 M 2,41 M
Net income 2020	-192 M -23,2 M -23,2 M
Net cash position 2020	104 M 12,5 M 12,5 M
P/E ratio 2020	-10,5x
Yield 2020	-

Sales 2021	18,9 M 2,29 M 2,29 M
Net income 2021	-157 M -18,9 M -18,9 M
Net cash position 2021	128 M 15,4 M 15,4 M
P/E ratio 2021	-15,0x
Yield 2021	-

Capitalization	2 351 M 284 M 284 M
EV / Sales 2020	113x
EV / Sales 2021	117x
Nbr of Employees	12
Free-Float	100%

More Financials

Company

Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not...

Sector

Pharmaceuticals

Calendar

More about the company

Notations Surperformance© of Isofol Medical AB (publ)

Trading Rating :

Investor Rating :

More Ratings

All news about ISOFOL MEDICAL AB (PUBL)

2020	ISOFOL MEDICAL : reaches 440 patients in global Phase III AGENT study	AQ
2020	DNB MARKETS - ISOFOL MEDICAL : Full steam ahead	AQ
2020	DNB MARKETS : Isofol Medical - Licensing deal for Canada	AQ
2020	ISOFOL MEDICAL : Invitation to a conference call and webcast by Isofol in connec..	AQ
2020	ISOFOL MEDICAL : announces licensing agreement for Paladin Labs Inc. to commerci..	AQ
2020	ISOFOL MEDICAL : Positive Momentum Ahead of AGENT Verdict	AQ
2020	ISOFOL MEDICAL : 55 % Overall Response Rate on the safety extension cohorts of t..	AQ
2020	ISOFOL MEDICAL : Strengthened patent protection for arfolitixorin in Japan	AQ
2020	ISOFOL MEDICAL : DNB Markets - Good momentum in Q2	AQ
2020	DNB MARKETS - ISOFOL MEDICAL : Enters into licensing deal for Japan	AQ
2020	ISOFOL MEDICAL PUBL : Invitation to a conference call and webcast by Isofol in c..	AQ
2020	ISOFOL MEDICAL PUBL : enters licensing agreement with Solasia to develop and com..	AQ
2020	ISOFOL MEDICAL PUBL : CEO Ulf Jungnelius has subscribed for all warrants	PR
2020	ISOFOL MEDICAL PUBL : CEO Ulf Jungnelius has subscribed for all warrants	AQ
2020	ISOFOL MEDICAL PUBL : A milestone is reached with the inclusion of 330 patients ..	AQ

More news

News in other languages on ISOFOL MEDICAL AB (PUBL)

- No features available -

More news

Provided by Scoopnest.com

Chart ISOFOL MEDICAL AB (PUBL)

Duration : Period :

Isofol Medical AB (publ) Technical Analysis Chart | ISOFOL | SE0009581051 | MarketScreener

Full-screen chart

Technical analysis trends ISOFOL MEDICAL AB (PUBL)

	Short Term	Mid-Term	Long Term
Trends	Bullish	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	HOLD
Number of Analysts	4
Average target price	38,00 SEK
Last Close Price	28,20 SEK
Spread / Highest target	106%
Spread / Average Target	34,8%
Spread / Lowest Target	-25,5%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Jarl Ulf Birger Jungnelius	Chief Executive Officer & Director
Pär-Ola Mannefred	Chairman
Gustaf Albért	Chief Financial Officer
Karin Ganlöv	Senior Medical Director
Roger Tell	Chief Medical Officer

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

ISOFOL MEDICAL AB (PUBL)	0.71%	284



MERCK KGAA	0.53%	74 677
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD	11.98%	27 883
KYOWA KIRIN CO., LTD.	-1.28%	14 378
BETTA PHARMACEUTICALS CO., LTD.	33.28%	8 898
YUHAN CORPORATION	-3.60%	4 265

More Results